Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as μ opioid receptor antagonists with improved opioid receptor selectivity profiles

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 6, 2008, Pages 2006-2012

  Le Bourdonnec, Bertrand ^a   Barker, William M ^a   Belanger, Serge ^a   Wiant, Daniel D ^a   Conway James, Nathalie C ^a   Cassel, Joel A ^a   O'Neill, Timothy J ^a   Little, Patrick J ^a   DeHaven, Robert N ^a   DeHaven Hudkins, Diane L ^a   Dolle, Roland E ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

receptors; Opioid; Solid phase synthesis

Indexed keywords

3,4 DIMETHYL 4 (3 HYDROXYPHENYL)PIPERIDINE; ALVIMOPAN; LOPERAMIDE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; OPIATE RECEPTOR; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; SOLID PHASE SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPRENORPHINE; GASTROINTESTINAL TRANSIT; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LOPERAMIDE; MICE; MOLECULAR STRUCTURE; PIPERIDINES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 40749139396     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.106     Document Type: Article

References (17)

1. Kurz A., and Sessler D.I. Drugs 63 (2003) 649
2. Zimmerman D.M., Gidda J.S., Cantrell B.E., Schoepp D.D., Johnson B.G., and Leander J.D. J. Med. Chem. 37 (1994) 2262
3. Neary P., and Delaney C.P. Expert Opin. Invest. Drugs 14 (2005) 479
4. Zimmerman D.M., Nickander R., Horng J.S., and Wong D.T. Nature 275 (1978) 332
5. Zimmerman D.M., Leander J.D., Cantrell B.E., Reel J.K., Snoddy J., Mendelsohn L.G., Johnson B.G., and Mitch C.H. J. Med. Chem. 36 (1993) 2833
6. Mitch C.M., Leander J.D., Mendelsohn L.G., Shaw W.N., Wong D.T., Cantrell B.E., Johnson B.G., Reel J.K., Snoddy J.D., Takemori A.E., and Zimmerman D.M. J. Med. Chem. 36 (1993) 2842
7. Thomas J.B., Mascarella S.W., Rothman R.B., Partilla J.S., Xu H., McCullough K.B., Dersch C.M., Cantrell B.E., Zimmerman D.M., and Carroll F.I. J. Med. Chem. 41 (1998) 1980
8. For a full description of the biological methods, see: Schlechtingen, G.; DeHaven, R. N.; Daubert, J. D.; Cassel, J. A.; Chung, N. N.; Schiller, P. W.; Taulane, J. P.; Goodman, M. sequence. Structure-activity relationships of dynorphin A analogs modified in the address J. Med. Chem. 2003, 46, 2104.
9. Werner J.A., Cerbone L.R., Frank S.A., Ward J.A., Labib P., Tharp-Taylor R.W., and Ryan C.W. J. Org. Chem. 61 (1996) 587
10. Szardenings A.K., Burkoth T.S., Look G.C., and Campbell D.A. J. Org. Chem. 61 (1996) 6720
11. Combs A.P., Tadesse S., Rafalski M., Haque T.S., and Lam P.Y.S. J. Comb. Chem. 4 (2002) 179
12. Fukuyama T., Jow C.-K., and Cheung M. Tetrahedron Lett. 36 (1995) 6373
13. Mitsunobu O. Synthesis (1981) 1
14. Lin X., Dorr H., and Nuss J.M. Tetrahedron Lett. 41 (2000) 3309
15. 35S]GTPγS) binding to membranes containing δ opioid receptors.
16. In vivo test methods: (a) Gastrointestinal Transit (GIT) assay: Male Swiss-Webster mice (20-25 g) were fasted overnight prior to the experiment. Mice were treated with vehicle (10% DMSO:20% cremophor EL:70% saline), or test compound (administered using the subcutaneous route). Twenty-five minutes after administration of vehicle or tested compound, the mice were treated with morphine (3 mg/kg s.c.), and 10 min later received 0.3 mL of a charcoal meal consisting of charcoal:flour:water (1:2:8, w/w/v). Gastrointestinal transit (GIT) was measured 25 min after the administration of the charcoal meal. GIT was determined by removing the entire length of the small intestine and measuring how far the leading edge of the charcoal meal traveled in the small intestine; % GIT was determined by the following formula: % GIT = [distance to charcoal leading edge (cm)/length of small intestine (cm)] × 100. (b) Assessment of physical dependence: male Swiss-Webster mice (30-35 g) were implanted with a placebo or a 75 mg morphine base pellet (Murty Pharmaceuticals, Inc., Lexington, KY). Three days after the pellet implantation, mice were treated with vehicle (10% DMSO:20% Cremophor EL:70% Saline) or test compound (administered using the subcutaneous route at the dose of 10 mg/kg). Immediately after the treatment, the mice were placed in individual plastic observation cylinders (26 cm high × 22 cm diameter) and the number of jumps and other abstinence behaviors were recorded for a 10 min period. One hour after the treatment, the incidence of diarrhea was assessed as absent or present for each mouse and a post treatment body weight was obtained.
17. Le Bourdonnec, B.; Dolle, R. E. U.S. Patent 254218, 2004.